image

Anti-Fungal Treatment Market Report Scope & Overview:

The Anti-Fungal Treatment Market Size was valued at USD 16.83 billion in 2023, and is expected to reach USD 22.82 billion by 2031 and grow at a CAGR of 3.88% over the forecast period 2024-2031.

Antifungal treatment, sometimes referred to as antimycotic treatment, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycoses such cryptococcal meningitis, candidiasis, ringworm, and others. To treat fungal infections, many antifungal medications are available. Antifungal drugs come in many distinct varieties. They may also be administered intravenously, topically, or orally. The rise in nosocomial and fungal diseases is the key factor driving the market for antifungal treatment. However, it is anticipated that a spike in initiatives by individuals and private organisations to raise awareness about the wide range of fungal illnesses will expand the global markets for antifungal treatments.

Anti-Fungal Treatment Market Revenue Analysis

Get More Information on Anti-Fungal Treatment Market - Request Sample Report

MARKET DYNAMICS

DRIVERS

  • Awareness of the Many Fungal Infections is Growing

  • More and more over-the-counter antifungal medications (OTC)

  • Antifungal Drug Use for a Wide Range of Medical Conditions is Growing in Developing Regions

RESTRAINTS

  • Issues with Medicine

  • Drug Resistance to Antifungals is Growing

  • Antifungal Drug Adverse Reactions

OPPORTUNITIES

  • R&D activities are becoming more prevalent.

CHALLENGES

  • Antifungal medications have a high price tag.

  • Resistance to antifungal drugs is spreading throughout the people

  • Underdeveloped countries' inadequate healthcare infrastructure

IMPACT OF COVID-19

Over the projected period, it is expected that the COVID-19 outbreak would constrain the market for antifungal medications. the COVID-19 virus has spread to almost every nation on earth, prompting the World Health Organization (WHO) to declare it a public health emergency. A new coronavirus called COVID-19 was identified as the cause of the pneumonia cases. Rapid global spread of this virus resulted in a large number of fatalities. the WHO proclaimed COVID-19 a global pandemic and recommended stringent measures to stop the disease's spread. Since then, the pandemic has delayed the growth of the healthcare sector and disrupted the supply chain.

Flight restrictions had an effect on the market for antifungal drugs in the first quarter. Strict social distancing laws and supply chain disruptions have had an impact on the antifungal drug industry. However, the market for antifungal medications, which had been languishing, has been revived as a result of economies unblocking during the second quarter. Government officials in the majority of countries have also imposed nationwide lockdowns in an effort to halt the spread of COVID-19. Similar issues were plaguing health systems around the world that made it difficult to keep up supply chains. The demand for antifungal drugs has also been hampered by the supply chain's slowness.

By Drug Class

The market was led by the azoles segment, and this trend is anticipated to persist over the projected period due to an increase in the occurrence of invasive fungal infections and the prevalence of diabetes. As a result, the market is growing due to the increase in antifungal medicine usage.

By Infection Type

Due to an increase in aspergillosis instances and a rise in the manufacturing of oral or intravenous medications like voriconazole, which can treat the invasive kind of aspergillosis, the systematic antifungal infection segment has been driving market expansion. But because there are more cases of candidiasis, a yeast-caused fungal infection, that segment of the market for superficial antifungal infections is anticipated to develop significantly throughout the projected period.

By Therapeutic Indications

The candidiasis segment is driving market expansion. Candidiasis is a fungal infection brought on by yeasts and is classified as belonging to the genus Candida as a result of the increase in candida organism proliferation. But due to an increase in aspergillus molds, the aspergillosis segment is anticipated to have significant growth during the projection period.

MARKET SEGMENT

By Drug Class

  • Azoles

  • Polyenes

  • Allylamines

  • Echinocandins

By Infection Type

  • Superficial Antifungal Infections

  • Systemic Antifungal Infections

By Therapeutic Indications

  • Aspergillosis

  • Dermatophytosis

  • Candidiasis

  • Others

By Dosage Forms

  • Oral

  • Topical

  • Others

REGIONAL ANALYSIS

Due to the rising rate of mucormycotic cases, the presence of major players, the growth of the healthcare industry, and the availability of new anti-fungal medications in the region, North America currently holds the largest market share for antifungal drugs and is predicted to maintain this position throughout the forecast period. Due to the rising prevalence of mucormycotic, a chronic illness-related fungal infection, Asia-Pacific is anticipated to see the highest CAGR throughout the projection of the market for antifungal medications.

Anti-Fungal-Treatment-Market-By-Region

Need any customization research on Anti-Fungal Treatment Market - Enquiry Now

REGIONAL COVERAGE

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

KEY PLAYERS:

Some of the major key players are as follows: Abbott, bioMérieux SA, Cardinal Health, Inc., F. Hoffmann-La Roche Ltd, BD, General Electric Company, Hologic, Inc, Siemens Medical Solutions USA, Inc., Quest Diagnostics Incorporated, Koninklijke Philips N.V. and Others Players.

General Electric Company-Company Financial Analysis

Company Landscape Analysis

Anti-Fungal Treatment Market Report Scope:
Report Attributes Details
Market Size in 2023 US$ 16.84 Billion
Market Size by 2031 US$ 22.87 Billion
CAGR CAGR of 3.9% From 2024 to 2031
Base Year 2023
Forecast Period 2024-2031
Historical Data 2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Drug Class (Azoles, Polyenes, Allylamines, Echinocandins)
• By Infection Type (Superficial Antifungal Infections, Systemic Antifungal Infections)
• By Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others)
• By Dosage Forms (Oral, Topical, Others)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Abbott, bioMérieux SA, Cardinal Health, Inc., F. Hoffmann-La Roche Ltd, BD, General Electric Company, Hologic, Inc, Siemens Medical Solutions USA, Inc., Quest Diagnostics Incorporated, Koninklijke Philips N.V.
Key Drivers • Awareness of the Many Fungal Infections is Growing
• More and more over-the-counter antifungal medications (OTC)
RESTRAINTS • Issues with Medicine
• Drug Resistance to Antifungals is Growing

Frequently Asked Questions

Ans. Anti-Fungal Treatment Market Size was valued at USD 16.83 billion in 2023.

Ans: The Anti-Fungal Treatment Market is growing at a CAGR of 3.88% over the forecast period 2024-2031.

Ans. North America currently holds the largest market share for antifungal market.

Ans. Manufacturer and service provider, research institutes, university and private libraries, suppliers and distributers

Ans. Anti-Fungal Treatment market is divided in four segments and they are By Drug Class, By Infection Type, By Therapeutic Indications, and By Dosage Forms

Table of Contents

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies

4.3.2.1 US

4.3.2.2 Canada

4.3.2.3 Germany

4.3.2.4 France

4.3.2.5 United Kingdom

4.3.2.6 China

4.3.2.7 Japan

4.3.2.8 South Korea

4.3.2.9 Rest of the World

 

5. Value Chain Analysis

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. Anti-Fungal Treatment Market Segmentation, By Drug Class

8.1 Azoles

8.2 Polyenes

8.3 Allylamines

8.4 Echinocandins

9. Anti-Fungal Treatment Market Segmentation, By Infection Type

9.1 Superficial Antifungal Infections

9.2 Systemic Antifungal Infections

10. Anti-Fungal Treatment Market Segmentation, By Therapeutic Indications

10.1 Aspergillosis

10.2 Dermatophytosis

10.3 Candidiasis

10.4 Others

11. Anti-Fungal Treatment Market Segmentation, By Dosage Forms

11.1 Oral

11.2 Topical

11.3 Others

12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Italy

12.3.5 Spain

12.3.6 The Netherlands

12.3.7 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 South Korea

12.4.3 China

12.4.4 India

12.4.5 Australia

12.4.6 Rest of Asia-Pacific

12.5 The Middle East & Africa

12.5.1 Israel

12.5.2 UAE

12.5.3 South Africa

12.5.4 Rest

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Rest of Latin America

13. Company Profiles

13.1 Abbott

13.1.1 Financial

13.1.2 Products/ Services Offered

13.1.3 SWOT Analysis

13.1.4 The SNS view

13.2 bioMérieux SA

13.3 Cardinal Health, Inc.

13.4 F. Hoffmann-La Roche Ltd

13.5 BD

13.6 General Electric Company

13.7 Hologic, Inc

13.8 Siemens Medical Solutions USA, Inc.

13.9 Quest Diagnostics Incorporated

13.10 Koninklijke Philips N.V.

14. Competitive Landscape

14.1 Competitive Benchmark

14.2 Market Share Analysis

14.3 Recent Developments

15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone